184 related articles for article (PubMed ID: 22509329)
1. Thrombospondin-1 type 1 repeats in a model of inflammatory bowel disease: transcript profile and therapeutic effects.
Lopez-Dee ZP; Chittur SV; Patel B; Stanton R; Wakeley M; Lippert B; Menaker A; Eiche B; Terry R; Gutierrez LS
PLoS One; 2012; 7(4):e34590. PubMed ID: 22509329
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model.
Gutierrez LS; Ling J; Nye D; Papathomas K; Dickinson C
World J Gastroenterol; 2015 May; 21(20):6157-66. PubMed ID: 26034351
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.
Lopez-Dee ZP; Chittur SV; Patel H; Chinikaylo A; Lippert B; Patel B; Lawler J; Gutierrez LS
PLoS One; 2015; 10(10):e0139918. PubMed ID: 26461935
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
[TBL] [Abstract][Full Text] [Related]
7. Role of TNFR-related 2 mediated immune responses in dextran sulfate sodium-induced inflammatory bowel disease.
Kim WK; Park JS; Sul OJ; Seo JH; Choi BK; Park HY; Latour AM; Koller BH; Kwon BS; Jeong CS
Mol Cells; 2011 Feb; 31(2):99-104. PubMed ID: 21347711
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Delic M; Lawler J; Parangi S
Clin Cancer Res; 2005 Mar; 11(6):2337-44. PubMed ID: 15788685
[TBL] [Abstract][Full Text] [Related]
10. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease.
Lu F; Fernandes SM; Davis AE
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G878-83. PubMed ID: 20338925
[TBL] [Abstract][Full Text] [Related]
11. Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease.
Zak S; Treven J; Nash N; Gutierrez LS
Int J Colorectal Dis; 2008 Mar; 23(3):297-304. PubMed ID: 18043928
[TBL] [Abstract][Full Text] [Related]
12. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
13. Cux1 transcription factor is induced in inflammatory bowel disease and protects against experimental colitis.
Darsigny M; St-Jean S; Boudreau F
Inflamm Bowel Dis; 2010 Oct; 16(10):1739-50. PubMed ID: 20848487
[TBL] [Abstract][Full Text] [Related]
14. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.
Wang Y; Mao Y; Zhang J; Shi G; Cheng L; Lin Y; Li Y; Zhang X; Zhang Y; Chen X; Deng J; Su X; Dai L; Yang Y; Zhang S; Yu D; Wei Y; Deng H
J Cell Mol Med; 2018 Feb; 22(2):1014-1025. PubMed ID: 29193791
[TBL] [Abstract][Full Text] [Related]
15. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.
Zhang X; Connolly C; Duquette M; Lawler J; Parangi S
Cancer Lett; 2007 Mar; 247(1):143-9. PubMed ID: 16757110
[TBL] [Abstract][Full Text] [Related]
16. Roxadustat protect mice from DSS-induced colitis in vivo by up-regulation of TLR4.
Feng Z; Cheng Y; Wang Y; Qu S; Du J; Gao F; Liu C; Wang Q; Cai J
Genomics; 2023 Mar; 115(2):110585. PubMed ID: 36801437
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondins as anti-angiogenic therapeutic agents.
Vailhé B; Feige JJ
Curr Pharm Des; 2003; 9(7):583-8. PubMed ID: 12570805
[TBL] [Abstract][Full Text] [Related]
18. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Matuszewska K; Ten Kortenaar S; Pereira M; Santry LA; Petrik D; Lo KM; Bridle BW; Wootton SK; Lawler J; Petrik J
Gynecol Oncol; 2022 Jan; 164(1):154-169. PubMed ID: 34799137
[TBL] [Abstract][Full Text] [Related]
19. Zeolite-Containing Mixture Supplementation Ameliorated Dextran Sodium Sulfate-Induced Colitis in Mice by Suppressing the Inflammatory Bowel Disease Pathway and Improving Apoptosis in Colon Mucosa.
Lyu W; Jia H; Deng C; Saito K; Yamada S; Kato H
Nutrients; 2017 May; 9(5):. PubMed ID: 28481231
[TBL] [Abstract][Full Text] [Related]
20. Biophysical characterization, including disulfide bond assignments, of the anti-angiogenic type 1 domains of human thrombospondin-1.
Huwiler KG; Vestling MM; Annis DS; Mosher DF
Biochemistry; 2002 Dec; 41(48):14329-39. PubMed ID: 12450399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
